SG11201505587YA - Toxic aldehyde related diseases and treatment - Google Patents
Toxic aldehyde related diseases and treatmentInfo
- Publication number
- SG11201505587YA SG11201505587YA SG11201505587YA SG11201505587YA SG11201505587YA SG 11201505587Y A SG11201505587Y A SG 11201505587YA SG 11201505587Y A SG11201505587Y A SG 11201505587YA SG 11201505587Y A SG11201505587Y A SG 11201505587YA SG 11201505587Y A SG11201505587Y A SG 11201505587YA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- related diseases
- toxic aldehyde
- aldehyde related
- toxic
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 title 1
- 231100000331 toxic Toxicity 0.000 title 1
- 230000002588 toxic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/07—Aldehydes; Ketones
- C08K5/08—Quinones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/16—Nitrogen-containing compounds
- C08K5/17—Amines; Quaternary ammonium compounds
- C08K5/18—Amines; Quaternary ammonium compounds with aromatically bound amino groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361755613P | 2013-01-23 | 2013-01-23 | |
US201361901796P | 2013-11-08 | 2013-11-08 | |
PCT/US2014/012762 WO2014116836A2 (en) | 2013-01-23 | 2014-01-23 | Toxic aldehyde related diseases and treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201505587YA true SG11201505587YA (en) | 2015-08-28 |
Family
ID=51228191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201505587YA SG11201505587YA (en) | 2013-01-23 | 2014-01-23 | Toxic aldehyde related diseases and treatment |
Country Status (13)
Country | Link |
---|---|
US (7) | US9687481B2 (en) |
EP (1) | EP2948149A4 (en) |
JP (5) | JP6514114B2 (en) |
KR (2) | KR102435676B1 (en) |
CN (3) | CN111135171B (en) |
AU (2) | AU2014209387B2 (en) |
CA (2) | CA2898631C (en) |
HK (1) | HK1217439A1 (en) |
IL (1) | IL239735B (en) |
MX (2) | MX2015009383A (en) |
RU (2) | RU2018145691A (en) |
SG (1) | SG11201505587YA (en) |
WO (1) | WO2014116836A2 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2393768T3 (en) | 2005-05-26 | 2012-12-27 | Neuron Systems, Inc | Quinoline derivative for the treatment of retinal diseases |
CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
RU2015120478A (en) | 2012-12-20 | 2017-01-25 | Альдейра Терапьютикс, Инк. | PERI-CARBINOLES |
KR102435676B1 (en) | 2013-01-23 | 2022-08-24 | 알데이라 테라퓨틱스, 아이엔씨. | Toxic aldehyde related diseases and treatment |
US10111862B2 (en) | 2013-01-25 | 2018-10-30 | Aldeyra Therapeutics, Inc. | Traps in the treatment of macular degeneration |
JPWO2016021706A1 (en) * | 2014-08-08 | 2017-05-25 | カズマパートナーズ株式会社 | Fused heterocyclic compounds |
AU2016311158A1 (en) | 2015-08-21 | 2018-04-05 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
KR20180073553A (en) * | 2015-08-21 | 2018-07-02 | 알데이라 테라퓨틱스, 아이엔씨. | Aldehyde conjugates and uses thereof |
CN105085427B (en) * | 2015-08-21 | 2018-06-05 | 中国科学院广州生物医药与健康研究院 | A kind of benzo [d] isoxazole class compound and its application |
EP3419633A4 (en) | 2016-02-28 | 2019-10-30 | Aldeyra Therapeutics, Inc. | Treatment of allergic eye conditions with cyclodextrins |
EP3454858A4 (en) | 2016-05-09 | 2020-01-15 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
EP3500256A4 (en) * | 2016-08-22 | 2020-01-08 | Aldeyra Therapeutics, Inc. | Aldehyde trapping compounds and uses thereof |
JP2020511461A (en) * | 2017-03-16 | 2020-04-16 | アルデイラ セラピューティクス, インコーポレイテッド | Polymorphic compounds and their use |
AU2018348174A1 (en) * | 2017-10-10 | 2020-04-23 | Aldeyra Therapeutics, Inc. | Treatment of inflammatory disorders |
TWI685338B (en) * | 2017-12-14 | 2020-02-21 | 柯瑞 伊里阿斯 J | Prevention and treatment of human metabolic syndrome including type 2 diabetes, steatohepatitis and related conditions using non-absorbable, orally administered compounds |
WO2020028820A1 (en) | 2018-08-03 | 2020-02-06 | Aldeyra Therapeutics, Inc. | Topical compositions and methods of preparation and use |
JP2021533154A (en) | 2018-08-06 | 2021-12-02 | アルデイラ セラピューティクス, インコーポレイテッド | Polymorphic compounds and their use |
CN113056353B (en) | 2018-09-25 | 2022-11-01 | 奥尔德拉医疗公司 | Formulation for treating dry eye |
WO2020198064A1 (en) | 2019-03-26 | 2020-10-01 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
CN113784954A (en) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | Polymorphic compounds and uses thereof |
EP3785694A1 (en) * | 2019-08-30 | 2021-03-03 | Hangzhou Ocean Pearl Industrial Co., Ltd. | Eyeliner product and method thereof |
US20230021669A1 (en) * | 2019-12-30 | 2023-01-26 | The National Institutes of Pharmaceutical R&D Co., Ltd. | Tricyclic compound, and preparation method therefor and medical use thereof |
WO2021211625A1 (en) * | 2020-04-13 | 2021-10-21 | Aldeyra Therapeutics, Inc. | Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions |
JP7488166B2 (en) | 2020-09-25 | 2024-05-21 | Jswアフティ株式会社 | Targets and deposition equipment |
WO2022143489A1 (en) * | 2020-12-29 | 2022-07-07 | 中国医药研究开发中心有限公司 | Tricyclic compound, and preparation method therefor and medical use thereof |
CN115843293A (en) * | 2021-06-25 | 2023-03-24 | 中国医药研究开发中心有限公司 | Tricyclic compound, preparation method and medical application thereof |
AU2022303386A1 (en) * | 2021-07-02 | 2023-12-14 | Aldeyra Therapeutics, Inc. | Heterocyclic aldehyde trapping compounds and uses thereof |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1020234A (en) | 1911-12-27 | 1912-03-12 | Charles Ward | Water-tube boiler. |
US2086186A (en) | 1933-10-10 | 1937-07-06 | Us Rubber Co | Treatment of rubber |
SU50906A1 (en) | 1935-12-20 | 1936-11-30 | А.И. Бурляев | Spindle for spinning machines |
GB1435721A (en) | 1972-05-18 | 1976-05-12 | Lilly Industries Ltd | Benzoxazole derivatives |
SU509046A1 (en) | 1975-02-21 | 1984-06-23 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Derivatives of 2-carbethoxy-3-aminoindole having antiinflammatory effect and process for preparing same |
JPS6192592A (en) | 1984-10-12 | 1986-05-10 | Norin Suisansyo Shokuhin Sogo Kenkyusho | Production of branched cyclodextrin |
US4675332A (en) | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
GB8610981D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Quinoline amides |
US5032392A (en) | 1986-09-04 | 1991-07-16 | Vision Pharmaceuticals | Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes |
NZ225045A (en) | 1987-07-01 | 1990-06-26 | Janssen Pharmaceutica Nv | Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent |
US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
BR9106193A (en) | 1990-10-22 | 1993-03-23 | Bausch & Lomb | METHOD AND COMPOSITION TO CLEAN CONTACT LENSES |
AU641052B2 (en) | 1990-11-02 | 1993-09-09 | Aventisub Ii Inc. | 3-amidoindolyl derivatives |
US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
TW401300B (en) | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
US5493027A (en) * | 1993-01-22 | 1996-02-20 | Board Of Regents, The University Of Texas System | Anticonvulsive agents and uses thereof |
US5767109A (en) | 1993-10-20 | 1998-06-16 | Sanchez; Robert A. | Complexing urushiols |
US5576311A (en) | 1994-11-30 | 1996-11-19 | Pharmos Corporation | Cyclodextrins as suspending agents for pharmaceutical suspensions |
JP3297969B2 (en) | 1994-12-26 | 2002-07-02 | ライオン株式会社 | Eye drops |
US5597823A (en) | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
JP3736916B2 (en) | 1996-02-19 | 2006-01-18 | 株式会社サンコンタクトレンズ | Disinfecting composition for hydrous soft contact lens and its use |
JP2001508029A (en) | 1996-08-01 | 2001-06-19 | ダウ・アグロサイエンス・エル・エル・シー | 4-substituted quinoline derivatives having fungicidal and fungicidal activity |
US5742954A (en) | 1996-11-22 | 1998-04-28 | Softub, Inc. | Electrically powered spa jet unit |
DE59813690D1 (en) | 1997-05-02 | 2006-09-28 | Schering Ag | SUBSTITUTED HETEROCYCLES AND THEIR USE IN MEDICINAL PRODUCTS |
JP2004500308A (en) | 1998-03-12 | 2004-01-08 | ノボ ノルディスク アクティーゼルスカブ | Modulator of protein tyrosine phosphatase |
US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
JP3568108B2 (en) | 1999-07-28 | 2004-09-22 | 松下電器産業株式会社 | Method for transmitting location information of digital map and apparatus for implementing the method |
AU1735001A (en) | 1999-12-10 | 2001-06-18 | Senju Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical composition |
US6569879B2 (en) | 2000-02-18 | 2003-05-27 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
JP4748289B2 (en) | 2000-06-23 | 2011-08-17 | ライオン株式会社 | Eye drops, ophthalmic composition, and adsorption suppression method |
FR2827599A1 (en) | 2001-07-20 | 2003-01-24 | Neuro3D | Treating central nervous system disorders, e.g. anxiety, depression, schizophrenia or pain, using new or known 2-substituted quinoline or quinoxaline derivatives having xanthenuric acid modulating action |
UA83620C2 (en) | 2001-12-05 | 2008-08-11 | Уайт | Substituted benzoxazoles and analogues as estrogenic agents |
US20060014786A1 (en) | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
US20040198828A1 (en) | 2003-01-17 | 2004-10-07 | Abelson Mark B. | Combinational use of long-acting and short-acting anti-histamines for ocular allergies |
US20040242704A1 (en) | 2003-03-14 | 2004-12-02 | University Of Washington, Techtransfer - Invention Licensing | Stabilized mutant opsin proteins |
DE602004030103D1 (en) | 2003-04-18 | 2010-12-30 | Advanced Medicine Res Inst | MEDIUM FOR THE TREATMENT OF DISEASES TO APPLY TO THE EYE |
US20060111318A1 (en) | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
US20040235892A1 (en) | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
JP2005132834A (en) | 2003-10-09 | 2005-05-26 | Kyowa Hakko Kogyo Co Ltd | Quinoline derivative |
US7563906B2 (en) | 2003-10-15 | 2009-07-21 | Ube Industries, Ltd. | Indazole derivatives |
EP1678160A1 (en) | 2003-10-27 | 2006-07-12 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
EP1689397A4 (en) * | 2003-11-20 | 2007-06-20 | Othera Pharmaceuticals Inc | Amelioration of macular degeneration and other ophthalmic diseases |
US20050197292A1 (en) | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
EP1722766A2 (en) | 2004-02-17 | 2006-11-22 | President And Fellows Of Harvard College | Management of ophthalmologic disorders, including macular degeneration |
US20050234018A1 (en) | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
JP2006008568A (en) | 2004-06-24 | 2006-01-12 | Cyclochem:Kk | IgE ANTIBODY-SUPPRESSING AGENT AND FOOD |
WO2006002473A1 (en) | 2004-07-02 | 2006-01-12 | Adelaide Research & Innovation Pty Ltd | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes |
FR2875409B1 (en) | 2004-09-17 | 2010-05-07 | Sanofi Aventis | PHARMACEUTICAL COMPOSITION COMPRISING A SOLID POLYMERIC MATRIX DISPERSION COMPRISING A CONTINUOUS PHASE OF POLYDEXTROSE AND A CONTINUOUS PHASE OF A POLYMER OTHER THAN POLYDEXTROSE |
US20070287716A1 (en) | 2004-10-28 | 2007-12-13 | Hu Essa H | Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors |
EP1844768A1 (en) | 2005-01-19 | 2007-10-17 | Dainippon Sumitomo Pharma Co., Ltd. | Aromatic sulfone compound as aldosterone receptor modulator |
TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
CN1830964B (en) * | 2005-03-11 | 2011-06-15 | 中国科学院上海药物研究所 | 4-Substituting anilino-3-nitroquinoline compounds, prepn. method and use thereof |
ES2393768T3 (en) | 2005-05-26 | 2012-12-27 | Neuron Systems, Inc | Quinoline derivative for the treatment of retinal diseases |
CN101351199B (en) | 2005-12-27 | 2013-01-02 | 狮王株式会社 | Composition for soft contact lens and adsorption suppressing method |
US20070297981A1 (en) | 2006-01-25 | 2007-12-27 | Ousler George W Iii | Formulations and methods for treating dry eye |
JP4466875B2 (en) | 2006-04-05 | 2010-05-26 | ライオン株式会社 | Eye drops for soft contact lenses |
ZA200809493B (en) | 2006-04-14 | 2010-08-25 | Prana Biotechnology Ltd | Method of treatment of age-related macular degeneration (AMD) |
JP5194218B2 (en) | 2006-06-05 | 2013-05-08 | 株式会社メニコンネクト | Preservation method of hydrous contact lens and hydrous contact lens preserved by the preservation method |
EP2079699A1 (en) | 2006-07-25 | 2009-07-22 | Envivo Pharmaceuticals, Inc. | Quinoline derivatives |
BRPI0716196A2 (en) | 2006-08-31 | 2013-11-12 | Eurand Inc | Drug delivery systems comprising solid solutions of weakly basic drugs. |
US8158609B1 (en) | 2006-11-02 | 2012-04-17 | Novartis Ag | Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen |
TW201242961A (en) | 2007-06-20 | 2012-11-01 | Ironwood Pharmaceuticals Inc | FAAH inhibitors |
RU2014151622A (en) * | 2007-10-05 | 2015-08-20 | Акусела Инк. | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES |
US8324270B2 (en) * | 2008-02-11 | 2012-12-04 | University Of Washington | Methods for the treatment and prevention of age-related retinal dysfunction |
KR20110044291A (en) | 2008-08-12 | 2011-04-28 | 서트리스 파마슈티컬즈, 인코포레이티드 | Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators |
WO2010107525A1 (en) | 2009-03-17 | 2010-09-23 | Aciex Therapeutics, Inc. | Ophthalmic formulations of ketotifen and methods of use |
WO2010133672A1 (en) | 2009-05-20 | 2010-11-25 | Clanotech Ab | Derivatives of quinoline-3-carboxylic acid and their medical use |
WO2010141834A1 (en) | 2009-06-05 | 2010-12-09 | Aciex Therapeutics, Inc. | Ophthalmic formulations of fluticasone and methods of use |
WO2010148351A1 (en) | 2009-06-18 | 2010-12-23 | Cylene Pharmaceuticals, Inc. | Rhodanines and related heterocycles as kinase inhibitors |
EP2477594A4 (en) | 2009-07-15 | 2013-03-13 | Univ Vanderbilt | Isoketal scavengers and mitigation of disorders involving oxidative injury |
TWI492769B (en) | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | Injectable aqueous ophthalmic composition and method of use therefor |
WO2011071995A2 (en) | 2009-12-08 | 2011-06-16 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
WO2011078204A1 (en) * | 2009-12-24 | 2011-06-30 | 浜理薬品工業株式会社 | Prophylactic or therapeutic agent for hyperlipemia, and anti-fatigue agent |
WO2011116066A1 (en) | 2010-03-17 | 2011-09-22 | Concert Pharmaceuticals, Inc. | Derivatives of dimethylcurcumin |
PL2663550T4 (en) | 2011-01-12 | 2017-07-31 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
US10463687B2 (en) | 2011-01-20 | 2019-11-05 | Cornell University | Treatments for retinal disorders |
CN103442735B (en) | 2011-01-31 | 2016-11-09 | 特米拉公司 | Active principle for undesirable medical condition in mitigation technique field |
TWI544922B (en) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | High concentration olopatadine ophthalmic composition |
US20130190500A1 (en) | 2011-12-12 | 2013-07-25 | Neuron Systems, Inc. | Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene |
NZ703992A (en) | 2012-08-01 | 2018-04-27 | Lewis And Clark Pharmaceuticals Inc | N-alkyl 2-(disubstituted)alkynyladenosine-5’-uronamides as a2a agonists |
RU2015120478A (en) | 2012-12-20 | 2017-01-25 | Альдейра Терапьютикс, Инк. | PERI-CARBINOLES |
KR102435676B1 (en) | 2013-01-23 | 2022-08-24 | 알데이라 테라퓨틱스, 아이엔씨. | Toxic aldehyde related diseases and treatment |
US10111862B2 (en) | 2013-01-25 | 2018-10-30 | Aldeyra Therapeutics, Inc. | Traps in the treatment of macular degeneration |
US9713330B1 (en) | 2013-03-15 | 2017-07-25 | Deuteria Agrochemicals, Llc | Deuterium-enriched aldehydes |
US20160151410A1 (en) | 2013-07-02 | 2016-06-02 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
US10272106B2 (en) | 2014-06-04 | 2019-04-30 | Case Western Reserve University | Compositions and methods of treating diabetic retinopathy |
NO2721710T3 (en) | 2014-08-21 | 2018-03-31 | ||
WO2016036674A1 (en) | 2014-09-02 | 2016-03-10 | Bhupinder Singh | Deuterated or a non-deuterated molecule and pharmaceutical formulations |
TW201628622A (en) | 2014-11-17 | 2016-08-16 | 製藥公司 | TLR inhibitor and BRUTON'S tyrosine kinase inhibitor combinations |
WO2016085939A2 (en) | 2014-11-24 | 2016-06-02 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
KR20180073553A (en) | 2015-08-21 | 2018-07-02 | 알데이라 테라퓨틱스, 아이엔씨. | Aldehyde conjugates and uses thereof |
AU2016311158A1 (en) | 2015-08-21 | 2018-04-05 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
EP3419633A4 (en) | 2016-02-28 | 2019-10-30 | Aldeyra Therapeutics, Inc. | Treatment of allergic eye conditions with cyclodextrins |
EP3454858A4 (en) | 2016-05-09 | 2020-01-15 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
US10844161B2 (en) | 2016-08-09 | 2020-11-24 | Covestro Deutschland Ag | Silane-functional polymeric polyurethanes |
EP3500256A4 (en) | 2016-08-22 | 2020-01-08 | Aldeyra Therapeutics, Inc. | Aldehyde trapping compounds and uses thereof |
WO2018039197A1 (en) | 2016-08-22 | 2018-03-01 | Aldeyra Therapeutics, Inc. | Aldehyde trapping compounds and methods of use thereof |
BR112019006160A2 (en) | 2016-09-28 | 2019-06-18 | Medicon Pharmaceuticals Inc | compositions and methods for treating ophthalmic conditions |
JP2020511461A (en) | 2017-03-16 | 2020-04-16 | アルデイラ セラピューティクス, インコーポレイテッド | Polymorphic compounds and their use |
AU2018348174A1 (en) | 2017-10-10 | 2020-04-23 | Aldeyra Therapeutics, Inc. | Treatment of inflammatory disorders |
WO2020018498A1 (en) | 2018-07-16 | 2020-01-23 | Aldeyra Therapeutics, Inc. | Cyclodextrin formulations |
WO2020028820A1 (en) | 2018-08-03 | 2020-02-06 | Aldeyra Therapeutics, Inc. | Topical compositions and methods of preparation and use |
JP2021533154A (en) | 2018-08-06 | 2021-12-02 | アルデイラ セラピューティクス, インコーポレイテッド | Polymorphic compounds and their use |
CN113056353B (en) | 2018-09-25 | 2022-11-01 | 奥尔德拉医疗公司 | Formulation for treating dry eye |
WO2020072621A1 (en) | 2018-10-02 | 2020-04-09 | Aldeyra Therapeutics, Inc. | Contact lens solutions and kits |
US20220133697A1 (en) | 2018-12-05 | 2022-05-05 | Aldeyra Therapeutics, Inc. | Injectable formulations |
WO2020198064A1 (en) | 2019-03-26 | 2020-10-01 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
CN113784954A (en) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | Polymorphic compounds and uses thereof |
WO2020223717A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
WO2021195211A1 (en) | 2020-03-24 | 2021-09-30 | Aldeyra Therapeutics, Inc. | Quinoline compounds for treating respiratory disorders and viral infections |
WO2021211625A1 (en) | 2020-04-13 | 2021-10-21 | Aldeyra Therapeutics, Inc. | Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions |
CN115697336A (en) | 2020-05-13 | 2023-02-03 | 奥尔德拉医疗公司 | Pharmaceutical preparation and use thereof |
CN115943314A (en) | 2020-06-04 | 2023-04-07 | 奥尔德拉医疗公司 | Biomarkers for dry eye disease and therapeutic uses thereof |
-
2014
- 2014-01-23 KR KR1020217011262A patent/KR102435676B1/en active IP Right Grant
- 2014-01-23 AU AU2014209387A patent/AU2014209387B2/en active Active
- 2014-01-23 CN CN202010058756.7A patent/CN111135171B/en active Active
- 2014-01-23 EP EP14743711.5A patent/EP2948149A4/en active Pending
- 2014-01-23 CN CN202311132218.8A patent/CN117045653A/en active Pending
- 2014-01-23 RU RU2018145691A patent/RU2018145691A/en not_active Application Discontinuation
- 2014-01-23 RU RU2015126016A patent/RU2676694C9/en active
- 2014-01-23 JP JP2015553925A patent/JP6514114B2/en active Active
- 2014-01-23 CA CA2898631A patent/CA2898631C/en active Active
- 2014-01-23 WO PCT/US2014/012762 patent/WO2014116836A2/en active Application Filing
- 2014-01-23 SG SG11201505587YA patent/SG11201505587YA/en unknown
- 2014-01-23 CN CN201480005853.2A patent/CN105120866B/en active Active
- 2014-01-23 US US14/760,039 patent/US9687481B2/en active Active
- 2014-01-23 KR KR1020157022673A patent/KR102243169B1/en active IP Right Grant
- 2014-01-23 CA CA3195807A patent/CA3195807A1/en active Pending
- 2014-01-23 MX MX2015009383A patent/MX2015009383A/en unknown
-
2015
- 2015-07-01 IL IL239735A patent/IL239735B/en active IP Right Grant
- 2015-07-21 MX MX2019012878A patent/MX2019012878A/en unknown
-
2016
- 2016-05-12 HK HK16105462.0A patent/HK1217439A1/en unknown
-
2017
- 2017-05-09 US US15/590,708 patent/US10213395B2/en active Active
-
2018
- 2018-10-05 AU AU2018241154A patent/AU2018241154A1/en not_active Abandoned
- 2018-10-22 JP JP2018198154A patent/JP7221021B2/en active Active
-
2019
- 2019-01-30 US US16/262,364 patent/US10543181B2/en active Active
- 2019-02-15 US US16/277,865 patent/US10588874B2/en active Active
-
2020
- 2020-01-27 US US16/773,654 patent/US11007157B2/en active Active
- 2020-02-25 JP JP2020029608A patent/JP2020079305A/en not_active Withdrawn
-
2021
- 2021-04-12 US US17/227,568 patent/US11701331B2/en active Active
-
2022
- 2022-03-07 US US17/653,827 patent/US11771664B2/en active Active
- 2022-09-22 JP JP2022151228A patent/JP7457401B2/en active Active
-
2024
- 2024-03-08 JP JP2024036019A patent/JP2024057103A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1217439A1 (en) | Toxic aldehyde related diseases and treatment | |
HK1222530A1 (en) | Microclosures and related methods for skin treatment | |
HK1222995A1 (en) | Tobacco material and treatment thereof | |
HK1220418A1 (en) | Methods for treating respiratory diseases and formulations therefor | |
HK1222552A1 (en) | Sobetirome in the treatment of myelination diseases | |
HK1254296A1 (en) | Therapeutic compounds and uses thereof | |
GB201320729D0 (en) | Therapeutic compounds and their use | |
HK1222994A1 (en) | Tobacco treatment | |
EP2953950A4 (en) | Compositions and methods for treating neurodegenerative diseases | |
HK1217092A1 (en) | Therapeutic compounds and uses thereof | |
HK1220352A1 (en) | Il-33 and treatment of neurodegenerative diseases il-33 | |
HRP20182173T1 (en) | Tobacco material and treatment thereof | |
HK1214093A1 (en) | Tobacco treatment | |
GB201311361D0 (en) | Compounds and their therapeutic use | |
ZA201603117B (en) | Withanolides useful for the treatment of neurodegenerative diseases | |
GB201308736D0 (en) | Compounds and their therapeutic use | |
GB201310798D0 (en) | Animal waste treatment | |
ZA201302565B (en) | Methods for treating hyperuricemia and related diseases | |
GB201317804D0 (en) | Therapeutic compounds and their use | |
GB201316173D0 (en) | Compounds and their therapeutic use | |
GB201307677D0 (en) | Compounds and their therapeutic use |